BCL2 and diffuse large B-cell lymphoma: Despite the observed synergism between PI3K/mTOR and BCL-2 inhibitors in these GCB-DLBCL lines, it is important to note that the magnitude of BAD and BIM accumulation induced by PI3K pathway suppression is insufficient to induce apoptosis.